Combined Triple Procedure in Retinal Vein Occlusion (RVO)
- Registration Number
- NCT00805064
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Brief Summary
The aim of this pilot study was to investigate the effects of an intravitreal combination therapy using triamcinolone and bevacizumab in patients with retinal vein occlusion (RVO).
- Detailed Description
This prospective study of a case series was conducted in 47 patients (n = 47 eyes; f/m: 21/26; mean age: 66.6 years) with ischemic central RVO (CRVO) (n = 15), non-ischemic CRVO (n = 7), or branch RVO (BRVO) (n = 25). A core pars plana vitrectomy with aspiration of 1.5 ml vitreous and infusion of balanced salt solution (BSS; 1 ml), 8 mg (0.4 ml) triamcinolone, and 1.25 mg (0.1 ml) bevacizumab was performed with a single sutureless sclerotomy and a 23 gauge probe tip. At baseline and follow-up, the best corrected visual acuity (BCVA; 6 m Snellen), and intraocular pressure (IOP; Goldmann tonometry), and central macular thickness (optical coherence tomography) were determined. In addition, the need for further treatment and adverse events were monitored.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- Ischemic central RVO (CRVO)
- Non-ischemic CRVO
- Branch RVO (BRVO)
- Visual deterioration due to acute or chronic inflammation
- Post trauma
- Macular edema of other origin
- Intravitreal drug treatment within last 4 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ischemic CRVO triamcinolone and bevacizumab treatment was applied to this entity non ischemic CRVO triamcinolone and bevacizumab treatment was applied to this entity BRVO triamcinolone and bevacizumab treatment was applied to this entity
- Primary Outcome Measures
Name Time Method BCVA day of exam
- Secondary Outcome Measures
Name Time Method